Oncology Xagena
Telomerase reverse transcriptase ( hTERT ) represents an attractive target for cancer immunotherapy because hTERT is reactivated in most human tumors. A Phase 1-2 clinical trial evaluated telomeras ...
Researchers, led by Steven A. Rosenberg, M.D., at the National Cancer Institute ( NCI ), part of the National Institutes of Health , have found that patients with advanced melanoma who had not respond ...
A study has shown that the immune-stimulating hormone known as Interleukin-12 ( IL-12 ) can safely be administered with Interferon, another immune-system protein, as an experimental therapy for some c ...
A research has shown that the immune-stimulating hormone known as Interleukin-12 ( IL-12 ) can safely be administered with Interferon, another immune-system protein, as an experimental therapy for som ...
Researchers from Mayo Clinic Cancer Center have shown that the combination of Paclitaxel and Carboplatin appears to be effective for metastatic melanoma when traditional treatments have failed. The ...
A phase III clinical trial has shown that Lapatinib ( Tykerb ) slows cancer growth and improves survival in a subset of patients with an advanced renal cell carcinoma ( RCC ) that continued to grow de ...
Sunitinib ( Sutent ) is more effective than the current standard cytokine treatment given as an initial therapy for patients with advanced kidney cancer, also known as metastatic renal cell carcinoma ...
A study has found that men with advanced, often untreatable prostate cancer who received a therapeutic cancer vaccine went on to survive longer than those receiving a placebo. Study findings showed ...
Active cellular immunotherapy is an approach that uses live human cells to re-engage the patient's own immune system. The goal of active cellular immunotherapy is to turn the immune system back on to ...
Dendreon announced publication of results from a Phase 1 study of Neuvenge, an investigational active cellular immunotherapy, in the Journal of Clinical Oncology. The article highlights the safety p ...
A study of nearly 1,500 patients treated for kidney cancer at UCLA ( University of California Los Angeles ) in the last 15 years has shown that an aggressive, tailored treatment approach results in b ...
A study of nearly 1,500 patients treated for kidney cancer at UCLA ( University of California Los Angeles ) in the last 15 years has shown that an aggressive, tailored treatment approach results in ...
The MAGE-A3 protein is expressed in approximately 35% of patients with resectable non-small-cell lung cancer ( NSCLC ). Several immunization approaches against the MAGE-A3 antigen have shown few, but ...
Important new data on MPDL3280A ( RG7446, also known as anti-PDL1 ) were presented at the 2013 European Cancer Congress ( ECC ).The data from an updated analysis of a Phase 1 study assessing MPDL3280A ...
Rresults from a pivotal phase 3 trial evaluating Talimogene Laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor ( GM- ...
